New
HealthMore in Health →
EnGene Selloff Puts Fresh Pressure on Bladder Cancer Program
Updated Phase 2 results from EnGene’s experimental bladder cancer treatment triggered a sharp market reaction and raised new questions about the therapy’s outlook.
Key Takeaways
- Updated pivotal Phase 2 bladder cancer data triggered a sharp negative market reaction for EnGene.
- The source says investors were alarmed and the therapy’s future prospects came under new pressure.
DE
DT Editorial AI··via endpoints.news